Related Experiment Video
Updated: Nov 7, 2025
12:23
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Published on: August 2, 2018
12.4K
Lipidomics as a Diagnostic Tool for Prostate Cancer
Magdalena Buszewska-Forajta1,2, Paweł Pomastowski3,4, Fernanda Monedeiro3,4
1Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Aleja Generała Józefa Hallera 107, 80-416 Gdańsk, Poland.
Cancers
|April 30, 2021
Summary
This study identified specific phospholipid alterations in prostate cancer (PCa) tissues using advanced mass spectrometry. These lipid changes show potential for developing new diagnostic tools for PCa detection.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Oncology
Background:
- Prostate cancer (PCa) development involves complex metabolic changes.
- Phospholipid alterations are implicated in various cancers, but specific markers for PCa require further investigation.
Purpose of the Study:
- To investigate phospholipid profile differences between PCa tissues and healthy controls.
- To identify specific lipid biomarkers for PCa diagnosis using mass spectrometry.
Main Methods:
- Analysis of phospholipid classes (phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, phosphatidylethanolamines) in PCa (n=40) and control (n=40) tissues.
- Utilized matrix-assisted laser desorption ionization with time-of-flight mass spectrometry (MALDI-TOF/MS) and electrospray ionization with triple quadrupole mass spectrometry (ESI-QqQ/MS).
- Applied univariate and multivariate statistical analyses for feature selection and relationship exploration.
Main Results:
- Identified distinct phospholipid alterations associated with PCa.
- Specific phospholipids, including PC 16:0/16:1, PC 16:0/18:2, and SM d18:1/24:0, demonstrated significant discriminative power.
- Results suggest a link between PCa, fatty acid synthesis, and lipid oxidation.
Conclusions:
- Phospholipid profiles differ significantly between PCa and control tissues.
- Specific phospholipids can serve as potential biomarkers for PCa.
- Lipidomics offers a promising avenue for developing alternative diagnostic tools for prostate cancer.
